Shockwave Medical

Shockwave Medical, Inc. operates as a medical device company, which focuses on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. The firm offers M5 catheters for treating above-the-knee peripheral artery disease, C2 catheters for treating coronary artery disease, and S4 catheters or treating below-the-knee peripheral artery disease. The company was founded by Daniel Hawkins, John M. Adams, and Todd J. Brinton in 2009 and is headquartered in Santa Clara, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

ShockWave Medical reports robust revenue growth and strategic expansion plans

ShockWave Medical's strong performance in Q4 and full year 2022 underscores its growth trajectory and market acceptance.
The company's strategic initiatives, including product approvals, acquisitions, and revenue outlook, position it for continued success in 2023.
While facing challenges in operational transitions and tax strategies, ShockWave Medical remains focused on leveraging opportunities for growth and market expansion.

Shockwave Medical reports stellar Q1 results and eyes global expansion

Shockwave Medical delivered robust Q1 2023 results, showcasing significant revenue growth and strong international performance.
The company's focus on market expansion, new product launches, and strategic acquisitions underpin its confidence in sustained growth.
While facing challenges such as staffing shortages and margin pressures, Shockwave Medical remains optimistic about its future prospects and market opportunities.
Continued investments in innovation, market expansion, and talent acquisition position the company well for future success and revenue growth.

Shockwave Medical reports robust Q2 earnings, eyes international growth

Shockwave Medical's strong financial performance in Q2 2023 reflects revenue growth, profitability, and operational efficiency.
Strategic investments, focus on market expansion, and upcoming product launches position the company for future success and revenue growth.
While facing challenges in product development and market uncertainties, Shockwave has opportunities for growth in international markets and product differentiation.

Shockwave Medical reports robust Q3 earnings and eyes global expansion

Shockwave Medical's strong Q3 performance, international growth, and promising product pipeline position the company for long-term success. Despite challenges in the U.S. peripheral business, the company remains confident in its evidence-backed interventions and overall growth potential. Strategic initiatives to address prior authorization issues and expand market presence underscore a proactive approach to sustaining growth.

Shockwave Medical reports record revenue and strategic growth initiatives

Shockwave Medical delivered strong financial performance in Q4 2023, with record revenue and profitability, driven by growth in key business segments and international markets.
The company's strategic focus on evidence-based market penetration, new product launches, and global expansion positions it for continued growth and market leadership.
Despite challenges in clinical evidence generation and reimbursement complexities, SWAV's proactive approach and financial strength offer resilience and growth opportunities.
SWAV's confidence in achieving milestones, expanding into new markets, and driving revenue growth through innovative products underscore a promising outlook for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shockwave Medical is developing the Lithoplasty™ family of balloon dilatation catheters that incorporate tiny lithotripsy electrodes designed to increase the compliance of rigid vascular and valvular lesions prior to low-pressure dilation, thereby limiting injury to healthy tissue and overcoming significant limitations of current revascularization technologies. The technology is built on traditional balloon catheter platforms rendering it inherently familiar and easy to use for cardiologists, interventional radiologists and vascular surgeons alike. In peripheral vessels, Lithoplasty™ could enable more effective angioplasty, less frequent bailout stent usage and enhanced lesion preparation prior to the use of drug eluting balloons (DEB) or bio-absorbable vascular scaffolds (BVS). In coronary vessels it could facilitate stent delivery and enhance vessel preparation prior to stent or BVS placement. Finally, in aortic valves the technology could vastly improve native tissue preparation prior to trans-catheter aortic valve replacement (TAVR) and valvuloplasty for those patients not suitable for TAVR.

Shockwave Medical (SWAV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Can Shockwave Medical (SWAV) Keep the Earnings Surprise Streak Alive?

Neovasc

Vancouver, British Columbia--(Newsfile Corp. - January 17, 2023) - Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive devices for the treatment of refractory angina, announced today that the Company has entered into a binding agreement (the "Arrangement Agreement") with Shockwave Medical, Inc. ("Shockwave"), whereby Shockwave has agreed to acquire all of the issued and outstanding common shares (the "Common Shares") of the Company (the "Transaction").

Shockwave Medical to Acquire Neovasc

Neovasc's Innovative Reducer System Will Target the Estimated $5 Billion Refractory Angina Market

Shockwave Medical Announces Agreement to Acquire Neovasc

Investors need to pay close attention to ShockWave Medical (SWAV) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in ShockWave Medical (SWAV) Stock?

SANTA CLARA, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it expects to issue quarterly earnings releases after the market closes and hold conference calls at the times indicated on the following dates:

Shockwave Medical Provides Quarterly Earnings Release Dates for 2023

Devon Energy

Eli Lilly

Cheniere Energy

Occidental Petroleum

Sociedad Quimica Y Minera De Chile

Exxon Mobil

The best retirement stocks for investors over 50 have reliability in common. Retirement stocks come in a few flavors, but the best retirement stocks for investors over 50 provide a mix of growth, stability and income.

The 7 Best Retirement Stocks for Investors Over 50

ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.

Here's Why You Should Bet on ShockWave Medical (SWAV) Stock

Investors who bought ShockWave Medical stock during the IPO in early 2019 have experienced a massive 570% share price growth. The company is gaining market share because it offers the best-in-class method of cracking calcium in arteries.

ShockWave Ultrasonic System Superior To Boston Scientific Laser Systems

ChampionX

Enphase Energy

LPL Financial Hlds

United Therapeutics

we have identified five non-technology Nasdaq stocks that have popped in 2022 despite the index's blood bath. These are: UTHR, LPLA, ENPH, SWAV, CHX.

Top 5 Non-Tech Nasdaq Winners of 2022 With More Upside Left

Lovesac Company

It's going to take more than a recession to stop these two from delivering outsized gains to patient investors.

2 Elite Growth Stocks Ready for a Bull Run in 2023

Shockwave Medical (SWAV) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

After Plunging 10.9% in 4 Weeks, Here's Why the Trend Might Reverse for Shockwave Medical (SWAV)

Shockwave Medical (SWAV) reported earnings 30 days ago. What's next for the stock?

Why Is Shockwave Medical (SWAV) Down 8.3% Since Last Earnings Report?

iRadimed

Tactile Systems

Here we discuss ShockWave Medical (SWAV), iRadimed (IRMD) and Tactile Systems Technology (TCMD), which have the potential to outperform their industry going forward.

3 Medical Instruments Stocks With Potential to Outperform

CrowdStrike

Pubmatic

The road ahead of these businesses is a lot smoother than you'd think by looking at their stock prices.

Nasdaq Bear Market: 3 Unstoppable Growth Stocks to Buy at Knocked-Down Prices

Dynatronics

Mesa Laboratories

The Zacks Medical - Instruments industry is growing on rising demand for digital health. SWAV, MLAB and DYNT are set to gain the most.

3 Medical Instruments Stocks to Buy as Inflation Clouds Prospects

SoFi Technologies

Trade Desk

Some of the world's most successful investors can't get enough of The Trade Desk, Shockwave Medical, and SoFi Technologies.

3 Beaten-Down Growth Stocks That Billionaires Are Buying With Both Hands

SANTA CLARA, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, announced today that the company will be participating in the Piper Sandler 34th Annual Virtual Healthcare Conference, scheduled to be held from November 29 to December 1, 2022.

Shockwave Medical to Participate in the Piper Sandler 34th Annual Healthcare Conference

SANTA CLARA, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the publication of its inaugural Environmental, Social and Governance (ESG) report highlighting the company's corporate responsibility and sustainability initiatives. The report includes 2021 performance highlights in key areas such as employee health and safety, diversity and inclusion, community impact, ethics and compliance, and environmental responsibility.

Shockwave Medical Publishes Inaugural ESG Report

CVS Health

One's a growth stock and the other pays a dividend but both of these healthcare businesses have what it takes to reliably outperform.

2 Stocks I'd Buy Right Now Without Hesitation

Macroeconomic pressures aren't much of an issue when all your customers are cardiovascular surgeons.

Here's the Best Growth Stock to Buy Right Now If You're Worried About a Recession

Shockwave Medical's (SWAV) third-quarter results reflect robust revenue growth and expansion in gross margin.

Shockwave Medical (SWAV) Beats on Q3 Earnings & Revenues

ShockWave Medical, Inc. (NASDAQ:SWAV ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Debbie Kaster - Vice President, Investor Relations Doug Godshall - President & Chief Executive Officer Isaac Zacharias - President & Chief Commercial Officer Dan Puckett - Chief Financial Officer Conference Call Participants Adam Maeder - Piper Sandler Bill Plovanic - Canaccord Michael Polark - Wolfe Research Nathan Treybeck - Wells Fargo Operator Good afternoon and welcome to Shockwave's Third Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

ShockWave Medical, Inc. (SWAV) Q3 2022 Earnings Call Transcript

SANTA CLARA, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September 30, 2022.

Shockwave Medical Reports Third Quarter 2022 Financial Results

Shockwave Medical's (SWAV) third-quarter results are likely to reflect solid performance of its IVL system across geographies.

What's in Store for Shockwave Medical (SWAV) in Q3 Earnings?

Caesars Entertainment

Fed Chair Jerome Powell made it somewhat clear this week that “pausing” was not an option just yet. (read more) That paints a not-so-healthy picture for stocks moving forward.

News for Shockwave Medical Stock (SWAV)